Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.
Epistemonikos ID: d3f48ac554ba6b436300f74eed4679c155770f8c
First added on: May 13, 2024